Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Vorinostat is a small molecule histone deacetylase (HDAC) inhibitor used for the treatment of cutaneous T-cell lymphoma (CTCL), particularly in patients with progressive, persistent, or recurrent disease following prior systemic therapies. It acts by inhibiting the enzymatic activity of HDAC1, HDAC2, and HDAC3 (Class I) and HDAC6 (Class II), leading to increased acetylation of histones and transcription factors. This results in an open chromatin structure that promotes gene transcription associated with cell cycle arrest and apoptosis in cancer cells. Vorinostat is administered orally as a capsule[1][2][3][5][8].
- Brand names
- Zolinza
- Other names
- suberanilohydroxamic acidoctanedioic acid hydroxyamide phenylamidevorinostatumSHH
02
Targets
HDAC6 (Histone deacetylase 6)HDAC1 (Histone Deacetylase 1)
Beyond the preview
Go deeper on vorinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat.